{"id":38760,"date":"2023-12-23T03:51:06","date_gmt":"2023-12-23T03:51:06","guid":{"rendered":"https:\/\/news.pakistaninewspaperlist.com\/iss-recommends-standard-biotools-stockholders-vote-for-all-proposals-relating-to-proposed-merger-with-somalogic\/"},"modified":"2023-12-23T03:51:06","modified_gmt":"2023-12-23T03:51:06","slug":"iss-recommends-standard-biotools-stockholders-vote-for-all-proposals-relating-to-proposed-merger-with-somalogic","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/iss-recommends-standard-biotools-stockholders-vote-for-all-proposals-relating-to-proposed-merger-with-somalogic\/","title":{"rendered":"ISS Recommends Standard BioTools Stockholders Vote \u201cFOR\u201d All Proposals Relating to Proposed Merger with SomaLogic"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) — Standard BioTools Inc.\u00a0(Nasdaq: LAB), driven by a bold purpose \u2013\u00a0Unleashing tools to accelerate breakthroughs in human health<\/em> – today announced that leading independent proxy advisory firm Institutional Shareholder Services (\u201cISS\u201d) has recommended that Standard BioTools stockholders vote \u201cFOR\u201d all proposals relating to the pending merger with SomaLogic at the Company\u2019s upcoming Special Meeting of Stockholders to be held on January 4, 2024. The Company issued the following statement:<\/p>\n

Our merger with SomaLogic presents a compelling value proposition for all stockholders through a significantly accelerated path to profitability and bolstered capital structure to fuel future growth. We are pleased with ISS\u2019 recommendation and look forward to completing the merger in the first quarter of 2024.<\/p>\n

A special meeting of Standard BioTools stockholders is scheduled to be held virtually in connection with the proposed merger on January 4, 2024, at 12:00 p.m. ET (10:00 a.m. MT \/ 9:00 a.m. PT). Standard BioTools\u00a0stockholders who need assistance voting or have questions regarding the Special Meeting may contact Standard BioTools\u2019 proxy solicitor,\u00a0Alliance Advisors LLC, at (800) 574-5969.\u00a0<\/p>\n

The merger remains on track to close in the first quarter of 2024, subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.<\/p>\n

About Standard BioTools Inc. <\/strong><\/p>\n

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose \u2013 Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter\u00ae, Facebook\u00ae, LinkedIn, and YouTube\u2122. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, \u201cUnleashing tools to accelerate breakthroughs in human health,\u201d Hyperion, Hyperion XTi, XTi, and X9 are trademarks and\/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and\/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.<\/p>\n

Additional Information and Where to Find It<\/strong><\/p>\n

In connection with the merger and required stockholder approval,\u00a0Standard BioTools\u00a0filed with the\u00a0U.S. Securities and Exchange Commission\u00a0(the \u201cSEC\u201d) a registration statement on Form S-4, as amended (the \u201cForm S-4\u201d), which was declared effective by the\u00a0SEC\u00a0on\u00a0December 1, 2023. The Form S-4 includes a definitive joint proxy statement of\u00a0Standard BioTools\u00a0and\u00a0SomaLogic\u00a0and also constitutes a final prospectus of\u00a0Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available to stockholders of\u00a0Standard BioTools\u00a0and\u00a0SomaLogic\u00a0on or about\u00a0December 4, 2023.\u00a0Standard BioTools\u2019 and SomaLogic\u2019s stockholders are urged to carefully read the joint proxy statement\/prospectus (including all amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the\u00a0SEC\u00a0and in their entirety because they contain important information about the merger and the parties to the merger.<\/strong>\u00a0Investors and stockholders may obtain free copies of these documents and other documents filed with the\u00a0SEC\u00a0at its website at\u00a0http:\/\/www.sec.gov<\/a>. In addition, investors may obtain free copies of the documents filed with the\u00a0SEC\u00a0by\u00a0Standard BioTools\u00a0at\u00a0http:\/\/investors.standardbio.com<\/a>\u00a0or contacting Standard BioTools\u2019 Investor Relations department at\u00a0investors@standardbio.com<\/a>\u00a0or at\u00a0https:\/\/investors.somalogic.com<\/a>\u00a0or by contacting SomaLogic Investor Relations at\u00a0investors@somalogic.com.\u00a0<\/a><\/p>\n

Participants in the Solicitation<\/strong><\/p>\n

Standard BioTools,\u00a0SomaLogic\u00a0and each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from\u00a0Standard BioTools stockholders with respect to the merger. Information about Standard BioTools\u2019 directors and executive officers, including their ownership of Standard BioTools\u2019 securities, is set forth in the joint proxy statement\/prospectus, Standard BioTools\u2019 proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the\u00a0SEC\u00a0on\u00a0April 28, 2023, Current Reports on Form 8-K, which were filed with the\u00a0SEC\u00a0on\u00a0May 3, 2023,\u00a0May 15, 2023,\u00a0June 16, 2023\u00a0and\u00a0July 28, 2023, and Standard BioTools\u2019 other filings with the\u00a0SEC. Information concerning SomaLogic\u2019s directors and executive officers, including their ownership of\u00a0SomaLogic\u00a0securities, is set forth in the joint proxy statement\/prospectus, SomaLogic\u2019s proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the\u00a0SEC\u00a0on\u00a0April 25, 2023, Current Reports on Form 8-K, which were filed with the\u00a0SEC\u00a0on\u00a0June 6, 2023, as amended on\u00a0June 14, 2023,\u00a0June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic\u2019s other filings with the\u00a0SEC. Investors may obtain more detailed information regarding the direct and indirect interests of\u00a0Standard BioTools\u00a0and its respective executive officers and directors in the merger, which may be different than those of Standard BioTools\u2019 stockholders generally, by reading the definitive proxy statements regarding the merger, which have been filed with the\u00a0SEC. These documents are available free of charge at the SEC\u2019s website at\u00a0www.sec.gov<\/a>, at\u00a0http:\/\/investors.standardbio.com<\/a>\u00a0or by contacting Standard BioTools\u2019 Investor Relations department at\u00a0investors@standardbio.com<\/a>\u00a0or at\u00a0https:\/\/investors.somalogic.com<\/a>\u00a0or by contacting SomaLogic Investor Relations at\u00a0investors@somalogic.com<\/a>.<\/p>\n

No Offer or Solicitation<\/strong><\/p>\n

This press release and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.<\/p>\n

Forward-Looking Statements<\/strong><\/p>\n

This press release\u00a0contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of the management of\u00a0Standard BioTools\u00a0and\u00a0SomaLogic\u00a0that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are beyond the control of\u00a0Standard BioTools\u00a0and\u00a0SomaLogic. All statements other than statements of historical fact (including statements containing the words \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates\u201d and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties\u2019 current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely affect Standard BioTools\u2019 and SomaLogic\u2019s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the merger and the potential failure to satisfy the conditions to the consummation of the merger, including obtaining stockholder and regulatory approvals; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the merger on the ability of\u00a0Standard BioTools\u00a0or\u00a0SomaLogic\u00a0to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom\u00a0Standard BioTools\u00a0or\u00a0SomaLogic\u00a0does business, or on Standard BioTools\u2019 or SomaLogic\u2019s operating results and business generally; (v) Standard BioTools\u2019 or SomaLogic\u2019s respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management\u2019s attention due to the merger; (vi) the outcome of any legal proceedings related to the merger or otherwise, or the impact of the merger thereupon; (vii)\u00a0Standard BioTools\u00a0or\u00a0SomaLogic\u00a0may be adversely affected by other economic, business and\/or competitive factors, (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the merger; (ix) restrictions during the pendency of the merger that may impact Standard BioTools\u2019 or SomaLogic\u2019s ability to pursue certain business opportunities or strategic transactions; (x) the risk that\u00a0Standard BioTools\u00a0or\u00a0SomaLogic\u00a0may be unable to obtain governmental and regulatory approvals required for the merger, or that required governmental and regulatory approvals may delay the consummation of the merger or result in the imposition of conditions that could reduce the anticipated benefits from the merger or cause the parties to abandon the merger; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the\u00a0Standard BioTools\u00a0shares to be issued in the merger; (xiv) the risk that post-closing integration of the merger may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company\u2019s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools\u2019 and SomaLogic\u2019s traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools\u2019 and SomaLogic\u2019s industry and individual companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of government resources; (xvii) the ability of\u00a0Standard BioTools\u00a0or\u00a0SomaLogic\u00a0to protect and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools\u2019 and SomaLogic\u2019s response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the \u201cRisk Factors\u201d section of Standard BioTools\u2019 most recent quarterly report on Form 10-Q filed with the\u00a0SEC\u00a0on\u00a0November 7, 2023, on its most recent annual report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0March 14, 2023\u00a0and in Standard BioTools\u2019 other filings with the\u00a0SEC, as well as the \u201cRisk Factors\u201d section of SomaLogic\u2019s most recent quarterly report on Form 10-Q filed with the\u00a0SEC\u00a0on\u00a0November 8, 2023, on its most recent annual report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0March 28, 2023\u00a0and in SomaLogic\u2019s other filings with the\u00a0SEC. The risks and uncertainties described above and in the\u00a0SEC\u00a0filings cited above are not exclusive and further information concerning\u00a0Standard BioTools\u00a0and\u00a0SomaLogic\u00a0and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management\u2019s reasonable estimates and beliefs as of the date of this press release. While\u00a0Standard BioTools\u00a0and\u00a0SomaLogic\u00a0may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.<\/p>\n

Contacts<\/strong><\/p>\n

Investors<\/p>\n

Standard BioTools
Peter DeNardo
CapComm Partners
ir@standardbio.com<\/a><\/p>\n

Media<\/p>\n

Nick Lamplough \/ Dan Moore \/ Tali Epstein
Collected Strategies
LAB-CS@collectedstrategies.com<\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) — Standard BioTools Inc.\u00a0(Nasdaq: LAB), driven by a bold purpose \u2013\u00a0Unleashing tools to accelerate breakthroughs in human health – today announced that leading independent proxy advisory firm Institutional Shareholder Services (\u201cISS\u201d) has recommended that Standard BioTools stockholders vote \u201cFOR\u201d all proposals relating to the pending merger […]<\/p>\n","protected":false},"author":2,"featured_media":38761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/122934c3-b763-4386-89d1-3047d0704c17","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-38760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/38760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=38760"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/38760\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/38761"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=38760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=38760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=38760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}